Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease...
-
UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapyTGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that...
-
Orphan Drug Designation confers regulatory, financial and strategic advantagesEO2463 has shown potentially disease modifying activity in clinical testing in watch-and-wait iNHL patientsEO2463 has...
-
UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapyTGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that...
-
EOM Receives FDA Clearance for Phase 2a Cancer Cachexia Trial
-
LifeArc partners with Elpida Therapeutics to advance gene therapies for three ultra-rare childhood diseases: SPG50, CLN7 and CMT4J.
-
60 Degrees Pharma enrolls first 2026 babesiosis trial patient ahead of schedule, supporting possible early interim analysis.
-
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients...
-
Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH ...
-
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...